105956-97-6

Basic information

• Product Name: Clinafloxacin
• Synonyms: 7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-8-chloro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid;CLINAFLOXACIN;3-Quinolinecarboxylic acid, 7-(3-amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-;6-Fluoro-8-chloro-1-cyclopropyl-7-(3-aminopyrrolidin-1-yl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid;7-(3-Amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid;7-(3-Amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid;7-(3-Aminopyrrolidin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid;CI-960
• CAS NO: 105956-97-6
• Molecular Formula: C₁₇H₁₇ClFN₃O₃
• Molecular Weight: 365.79
• Mol File: 105956-97-6.mol
• Article Data: 5

Chemical Properties

• Melting Point: 253-258 C
• Boiling Point: 592.3 °C at 760 mmHg
• Flash Point: 312 °C
• Appearance: /
• Density: 1.573 g/cm³
• Vapor Pressure: 7.14E-15mmHg at 25°C
• Refractive Index: 1.684
• Storage Temp.: 2-8°C
• Solubility: Acetic Acid (Slightly), DMSO (Slightly)
• PKA: 6.39±0.50(Predicted)
• CAS DataBase Reference: Clinafloxacin(CAS DataBase Reference)
• NIST Chemistry Reference: Clinafloxacin(105956-97-6)
• EPA Substance Registry System: Clinafloxacin(105956-97-6)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-63
• Safety Statements: 26-36-36/37
• RTECS: VB1800600
• Hazardous Substances Data: 105956-97-6(Hazardous Substances Data)

Usage

Description

Clinafloxacin is a fluoroquinolone antibiotic that possesses potent antibacterial properties. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV, which are essential for bacterial DNA replication, transcription, and repair. This action leads to the disruption of bacterial cell division and ultimately results in bacterial cell death.

Uses

Used in Medical Applications:
Clinafloxacin is used as an antibacterial agent for the treatment of various bacterial infections. Its broad-spectrum activity makes it effective against a wide range of gram-positive and gram-negative bacteria, including those that are resistant to other antibiotics. It is particularly useful in treating skin, respiratory, urinary, and gastrointestinal infections.
Used in Pharmaceutical Industry:
Clinafloxacin is used as an active pharmaceutical ingredient in the development of new drugs and formulations. Its potent antibacterial activity and ability to target multiple bacterial enzymes make it a valuable compound for the creation of innovative treatments for antibiotic-resistant infections.

InChI:InChI=1/C17H17ClFN3O3/c18-13-14-10(5-12(19)15(13)21-4-3-8(20)6-21)16(23)11(17(24)25)7-22(14)9-1-2-9/h5,7-9H,1-4,6,20H2,(H,24,25)

Upstream product

• 280-57-9 1,4-diaza-bicyclo[2.2.2]octane 
• 109-86-4 2-methoxy-ethanol 
• 101987-89-7 8-chloro-1-cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid 
• 79286-79-6 pyrrolidin-3-amine 
• 630-19-3 pivalaldehyde 
• 105956-96-5 7-[(3-t-Butoxycarbonylamino)-1-pyrrolidinyl]-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid 

Downstream Products

• 1395882-29-7 C₂₈H₂₇Cl₂FN₆O₄ 
• 1395882-28-6 C₂₉H₃₀ClFN₆O₄ 
• 1395882-30-0 C₂₈H₂₇ClF₂N₆O₄ 
• 1395882-33-3 C₂₈H₂₆Cl₃FN₆O₄ 
• 1395882-34-4 8-chloro-1-cyclopropyl-7-(3-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propylamino)pyrrolidin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1395882-32-2 C₂₈H₂₆ClF₃N₆O₄ 
• 1395882-31-1 C₂₈H₂₆Cl₃FN₆O₄ 

Relevant articles and documents

Method for making quinoline carboxylic acids or naphthyridine carboxylic acids in free base form

The present invention provides a method of making quinolone carboxylic acids or naphthyridine carboxylic acids in free base form, the method comprising dissolving a quinolone carboxylic acid salt or naphthyridine carboxylic acid salt in a solvent system to form a solution; combining the solution containing the quinolone carboxylic acid salt or naphthyridine carboxylic acid salt with a calcium salt in an amount in the range of about 0.01% to about 5.0% by weight of the quinolone carboxylic acid salt or naphthyridine carboxylic acid salt and a base, the combination resulting in the formation of a precipitate; and collecting the precipitate. Also provided is a solid bulk pharmaceutical chemical composition which is the product resulting from the precipitation.

Process for the synthesis of 3-chloro-2,4,5-trifluorobenzoic acid

An improved process for the preparation of 3-chloro-2,4,5-trifluorobenzoic acid is described which involves reaction of a diester of 3,4,5,6-tetrafluoro-1,2-benzenedicarboxylic acid with a substituted amine to afford 3-amino-2,4,5-trifluorobenzoic acid followed by subsequent conversion of the amio intermediate into 3-chloro-2,4,5-trifluorobenzoic acid.

Process and intermediates for quinolonecaboxylic acid

The present invention is concerned with a certain novel process for the preparation of a quinolonecarboxylic acid of the following formula; and with intermediates of the following formula; wherein R is hydrogen atom or lower alkyl group, X is halogen atom